824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
نویسندگان
چکیده
Mucormycosis Francisco M. Marty; John R. Perfect; Oliver A. Cornely; Kathleen M. Mullane; Galia Rahav; Misun Lee; Masanori Ito; Rochelle Maher; Bernhardt Zeiher; Luis Ostrosky-Zeichner; Brigham and Women’s Hospital Boston, MA; Duke University, Durham, NC; University Hospital of Cologne, Koeln, Germany; University of Chicago Medicine, Chicago, IL; Sheba Medical Center, Tel Hashomer, Israel; Astellas Pharma Global Development, Northbrook, IL; University of Texas, Houston, TX
منابع مشابه
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-bli...
متن کاملIsavuconazole as salvage therapy for mucormycosis
Mucormycosis carries a high mortality rate with few therapeutic options available. We describe a man with pulmonary/splenic mucormycosis complicating hypoplastic myelodysplastic syndrome on a background of chronic kidney disease, who achieved a complete response with salvage isavuconazole therapy following intolerance of consecutive courses of liposomal amphotericin and posaconazole therapy.
متن کاملIsavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavuconazole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic (PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole in patients treated in the ...
متن کاملIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double...
متن کاملImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole. Population analyses have demonstrated relatively predictable pharmacokinetic (PK) behavior in diverse patient populations. We evaluated the impact of mucositis on the oral isavuconazole exposure using population PK modeling. This study included patients treated in two phase 3 trials of isavuconazole, SECURE for treatment of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2014